| |
|
|
| |
Sustained Release Injectables
Evolving Formulations, Improving Dosing
Regimens
|
Publication: March 2011
Product Code: SRN3011K
|
The ability to formulate injectable drugs to increase the
duration of efficacy for a given dose and simultaneously
reduce the dosing frequency addresses several important
health care issues. Less frequent dosing is believed to
improve patient safety, reduce the incidence of injection
site complications and improve compliance with drug
protocols. Sustained release formulations mitigate the bolus
effect at the time of injection, and thus have a salutary
influence on drug side effects. All of these advantages,
along with the need for fewer patient caregiver visits (for
practitioner-administered drugs) have a positive, downward
impact on overall healthcare costs. Currently approved
sustained release injectables rely on a spectrum of branded
formulation technologies to modulate the drug’s release
profile post-injection. Typically off-patent or generic
drugs, they include drug therapies for almost a dozen major
therapeutic segments, including neurological conditions,
metabolic diseases, oncology, pain management and
reproductive health. As the incidence and prevalence of
chronic illnesses increases with the aging population, the
attraction and interest in sustained release injectables
will increase. |
|
Highlights |
· Provides detailed
analysis of sustained release injectable products,
market segments, market dynamics and market demographics
· Analyzes therapeutic
demand drivers and evaluates commercial sustained
release injectables in eleven major therapeutic segments
· Charts sustained
release product data and market share, and provides
forecasts to 2015
· Profiles sustained release
technology participants, their product
development activities, business strategies, and
corporate alliances and affiliations
|
|
Summary of Contents |
Executive Summary
Injectable Drug Market
Dynamics
The Trend toward Self-Administration
Shifting Demographics
Injectable Drug
Formulation Technology
Innovation in Injectable
Device Designs
Therapeutic Demand Drivers
Competitive Landscape
Risk Factors
Sustained Release Injectables - Branded Formulation
Technologies
Biodegradable Polymers
PEG
PLG/PLA/PLGA
Polyether ester
Other Polymers
ChroniJect
CriticalMix
Depofoam
LinkeRx
Liposomes
Medisorb
Medusa
Optisomes
OxtoDEX
SABER/SAIB
Sucrose acetate
isobutyrate
SynBiosys
Supercritical Fluid
Analysis of FDA Approved Sustained Release
Injectables
cytarabine
goserelin acetate
Interferon
lanreotide acetate
leuprolide
acetate
morphine
naltrexone
olanzapine
octreotide acetate
risperidone
paliperidone
palmitate
somatostatin
triptorelin pamoate
Development-Stage SR Injectable Drug
Candidate Assessment
Addiction
Antivirals
Hormones
Immune Modulators
Incretin Mimetics
Local Anesthetics
Opioid Antagonists
Psychotropics
Antineoplastics
SR
Injectables – Therapeutic Sector Impact Analysis &
Forecasts
Addiction
Autoimmune Diseases
Diabetes
Infectious Disease
Macular
Degeneration
Metabolic Diseases
Neurology
Oncology
Pain Management
Reproductive Health
Sustained Release Injectables – Company
Profiles
|
|
|
|
|
